Overview

Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

Status:
Active, not recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the effect of RO7049665 on time to relapse following forced corticosteroid (CCS) tapering as measured by the hazard ratio between RO7049665 7.5 milligrams (mg) and placebo arm.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche